Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin

NCT03736785 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03736785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03736785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2018
Completion date
February 18, 2020
Enrollment
399 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus